Veeva Clinical Database Crosses 200 Study Milestone
Veeva Clinical Database (CDB) enables methods of managing clinical trial data, which can save customers 30 to 50% of the time required to aggregate, clean, and transform data. Since Veeva Systems announced its launch, Veeva CDB has cleaned more than 200,000 subjects to provide quality data across more than 200 studies.
"By launching Veeva CDB and building processes around it, we're laying a foundation for clinical data transformation," said Jerry Yarem, vice president, data management, Fortrea in a press release. "This is a significant advancement that can bring together all of our data sources and deliver clean data faster than ever so study teams can make data-driven decisions with confidence."
Veeva CDB automates processes for a method of cleaning data that increases productivity and efficiency. Using Veeva CDB Auto Checks, customers can identify discrepancies upon data ingestion and create queries or close them when issues are corrected. The application also automates change detection so data managers can focus efforts on new or updated data, saving time and lowering costs.
"Veeva CDB makes collaboration with study partners and data providers easy, simplifying data transfer and configuration," said Tonya Arthur, head of data management, Acelyrin in a press release. "Pairing Veeva's clinical data management platform and our CRO partner's expertise will improve our trial processes and provide the visibility to make informed decisions that can positively impact trial outcomes."
Sponsors and contract research organizations (CROs) use Veeva CDB to ingest and clean clinical data from a variety of system sources, including EDC systems such as Veeva Vault EDC and Medidata Rave™, ePRO, and lab data. In addition, the Veeva CDB Data Provider Program enables qualified partners with resources to gain operational efficiencies when delivering data for Veeva CDB customers.
"Data transfers to and from Veeva enable an integrated service offering that streamlines data delivery for our joint customers using Veeva CDB and Clinical Ink's comprehensive suite of eCOA, direct data capture, patient engagement, and digital biomarker technologies," said Son Ly, vice president, data services, Clinical Ink in a press release.
"As clinical data sources continue to grow and trial complexity increases, data managers need agile technologies to streamline the path toward clean data and insights," said Pavel Burmenko, general manager, Veeva CDB in a press release. "With more than 30 data providers supplying study data, Veeva CDB is gaining momentum, advancing clinical data management for seamless information exchange and faster access to high-quality data."
Reference
Veeva Clinical Database Crosses 200 Study Milestone, Cuts Time to Aggregate and Clean Study Data by 30-50%. (2023, August 21). Cision PR Newswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
